RITTER PHARMACEUTICALS INC Contracts & Agreements

Director Agreement dated November 12, 2024 between the Company and Graydon Bensler (Filed With SEC on November 13, 2024)

Form of Placement Agency Agreement (Filed With SEC on October 24, 2024)

Form of Pre-Funded Warrant (Filed With SEC on October 24, 2024)

Form of Securities Purchase Agreement (Filed With SEC on October 24, 2024)

Form of Lock-Up Agreement (Filed With SEC on October 24, 2024)

Consulting Agreement, between the Company and IR Agency, LLC (Filed With SEC on October 24, 2024)

Director Agreement dated October 8, 2024 between the Company and Braeden Lichti (Filed With SEC on October 9, 2024)

Form of Pre-Funded Warrant (Filed With SEC on September 9, 2024)

Form of Placement Agent Warrant (Filed With SEC on September 9, 2024)

Placement Agent Agreement (Filed With SEC on September 9, 2024)

Form of Placement Agency Agreement (Filed With SEC on August 22, 2024)

Form of Pre-Funded Warrant (Filed With SEC on August 22, 2024)

Form of Securities Purchase Agreement (Filed With SEC on August 22, 2024)

Form of Placement Agency Warrant (Filed With SEC on August 22, 2024)

Form of Lock-Up Agreement (Filed With SEC on August 22, 2024)

Form of Placement Agency Agreement (Filed With SEC on August 9, 2024)

Form of Pre-Funded Warrant (Filed With SEC on August 9, 2024)

Form of Securities Purchase Agreement (Filed With SEC on August 9, 2024)

Form of Placement Agency Warrant (Filed With SEC on August 9, 2024)

Form of Lock-Up Agreement (Filed With SEC on August 9, 2024)

Form of Placement Agency Agreement (Filed With SEC on August 7, 2024)

Form of Pre-Funded Warrant (Filed With SEC on August 7, 2024)

Form of Securities Purchase Agreement (Filed With SEC on August 7, 2024)

Form of Placement Agency Warrant (Filed With SEC on August 7, 2024)

Form of Lock-Up Agreement (Filed With SEC on August 7, 2024)

Promissory Note, dated July 12, 2024, issued by Qualigen Therapeutics, Inc. to Marizyme, Inc (Filed With SEC on July 18, 2024)

Senior Note dated June 8, 2024 (Filed With SEC on July 15, 2024)

Securities Purchase Agreement dated July 5, 2024 (Filed With SEC on July 11, 2024)

Option Exercise dated April 11, 2024 by Yi Hua Chen, acknowledged by Alpha Capital Anstalt and by us (Filed With SEC on April 16, 2024)

8% Convertible Debenture dated April 12, 2024, issued by us to Yi Hua Chen (Filed With SEC on April 16, 2024)

Common Stock Purchase Warrant dated April 12, 2024, issued by us to Yi Hua Chen (Filed With SEC on April 16, 2024)

Co-Development Agreement dated April 11, between Marizyme, Inc. and us (Filed With SEC on April 16, 2024)

Termination Agreement dated as of March 16, 2024 between the Company and Pan-RAS Holdings, Inc (Filed With SEC on March 28, 2024)

Securities Purchase Agreement dated February 26, 2024 between the Company and Alpha Capital Anstalt (Filed With SEC on February 27, 2024)

Form of 8% Convertible Debenture to be issued by the Company to Alpha Capital Anstalt [Exhibit A to the Securities Purchase Agreement dated February 26, 2024] (Filed With SEC on February 27, 2024)

Form of Common Stock Purchase Warrant to be issued by the Company to Alpha Capital Anstalt [Exhibit C to the Securities Purchase Agreement dated February 26, 2024] (Filed With SEC on February 27, 2024)

License and Sublicense Agreement dated February 15, 2024 between the Company and Pan-RAS Holdings, Inc (Filed With SEC on February 22, 2024)

Amendment No. 1 with regard to Securities Purchase Agreement, dated December 5, 2023, between the Company and Alpha Capital Anstalt (Filed With SEC on December 7, 2023)

Consent and Waiver, dated September 22, 2023, between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt (Filed With SEC on September 28, 2023)

Separation Agreement and General Release, dated June 20, 2023, by and between Qualigen Therapeutics, Inc. and Amy Broidrick (Filed With SEC on August 14, 2023)

Stock Purchase Agreement, dated July 20, 2023, by and between Qualigen Therapeutics, Inc., Chembio Diagnostics, Inc., Biosynex, S.A., and Qualigen, Inc (Filed With SEC on July 26, 2023)

Amendment and Settlement Agreement, dated July 20, 2023, by and between Qualigen Therapeutics, Inc. and Nanosynex Ltd (Filed With SEC on July 26, 2023)

Amendment 1 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021 (Filed With SEC on May 2, 2023)

Amendment 2 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated January 17, 2023 (Filed With SEC on May 2, 2023)

Exclusive License Agreement between the Company and University of Louisville Research Foundation (RAS), Inc., dated as of July 17, 2020 (Filed With SEC on May 2, 2023)

Amendment 1 to the Exclusive License Agreement (RAS), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021 (Filed With SEC on May 2, 2023)

First Deed of Variation to License Agreement with UCL Business Limited dated March 30, 2022 (Filed With SEC on May 2, 2023)

Letter to Michael P. Poirier, dated January 13, 2023, regarding compensatory changes (Filed With SEC on May 2, 2023)

Letter to Amy Broidrick, dated January 13, 2023, regarding compensatory changes (Filed With SEC on May 2, 2023)

Letter to Tariq Arshad, dated January 13, 2023, regarding compensatory changes (Filed With SEC on May 2, 2023)

Common Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022 (Filed With SEC on December 22, 2022)

Securities Purchase Agreement, dated December 21, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt (Filed With SEC on December 22, 2022)

8% Senior Convertible Debenture Due December 22, 2025 (Filed With SEC on December 22, 2022)

Registration Rights Agreement, dated December 22, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt (Filed With SEC on December 22, 2022)

Amendment No. 2 to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc (Filed With SEC on November 22, 2022)

Amendment No. 1 to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc (Filed With SEC on November 22, 2022)

Qualigen Therapeutics, Inc. 2022 Employee Stock Purchase Plan (Filed With SEC on November 14, 2022)

Master Agreement for the Operational and Technological Funding of NanoSynex between Qualigen Therapeutics, Inc. and NanoSynex Ltd., dated May 26, 2022 (Filed With SEC on June 2, 2022)

Pre-Funded Common Stock Purchase Warrant issued by the Company in favor of Alpha Capital Anstalt, dated May 26, 2022 (Filed With SEC on June 2, 2022)

Amended and Restated Common Stock Purchase Warrant to GreenBlock Capital LLC (300,000 shares) (Filed With SEC on May 13, 2022)

Amended and Restated Common Stock Purchase Warrant to Christopher Nelson (300,000 shares) (Filed With SEC on May 13, 2022)

Series B Preferred Share Purchase Agreement between the Company and NanoSynex Ltd. dated April 29, 2022 (Filed With SEC on May 13, 2022)

Share Purchase Agreement between the Company and Alpha Capital Anstalt dated April 29, 2022 (Filed With SEC on May 13, 2022)

Executive Employment Agreement dated December 10, 2021 with Amy Broidrick (Filed With SEC on March 31, 2022)

Second Amendment to Lease with Bond Ranch LP dated December 15, 2021 (Filed With SEC on March 31, 2022)

Securities Purchase Agreement, dated November 29, 2021 (Filed With SEC on December 1, 2021)

Placement Agency Agreement between Qualigen Therapeutics, Inc. and A.G.P./Alliance Global Partners, dated November 29, 2021 (Filed With SEC on December 1, 2021)

Waiver and Amendment between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt, dated November 29, 2021 (Filed With SEC on December 1, 2021)

Amendment to Technology Transfer Agreement between Yi Xin Zhen Duan Jishu (Suzhou) Ltd. and Qualigen, Inc., dated August 5, 2021 (Filed With SEC on November 15, 2021)

Amendment to 2020 Stock Incentive Plan (approved by the Board of Directors on April 27, 2021 and by the Stockholders on August 9, 2021) (Filed With SEC on November 15, 2021)

Hire offer letter from the Company to Tariq Arshad, dated April 22, 2021 (Filed With SEC on August 16, 2021)

Letter dated June 22, 2021 to A.G.P./Alliance Global Partners giving notice of termination of Sales Agreement (Filed With SEC on August 16, 2021)

Amendment to Distribution and Development Agreement between Sekisui Diagnostics, LLC and Qualigen, Inc., dated as of July 1, 2021 [signed August 2, 2021] (Filed With SEC on August 13, 2021)

Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated January 30, 2021 (Filed With SEC on May 14, 2021)

Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated March 1, 2021 (Filed With SEC on May 14, 2021)

Securities Purchase Agreement, dated December 16, 2020 (Filed With SEC on December 18, 2020)

Placement Agency Agreement between Qualigen Therapeutics, Inc. and A.G.P./Alliance Global Partners, dated December 15, 2020 (Filed With SEC on December 18, 2020)

Two-Year Common Stock Purchase Warrant for 1,348,314 shares, dated December 18, 2020 (Filed With SEC on December 18, 2020)

Deferred Common Stock Purchase Warrant for 842,696 shares, dated December 18, 2020 (Filed With SEC on December 18, 2020)

Prefunded Common Stock Purchase Warrant for 1,000,000 shares, dated December 18, 2020 (Filed With SEC on December 18, 2020)

Technology Transfer Agreement dated as of October 7, 2020 between Qualigen, Inc. and Yi Xin Zhen Duan Jishu (Suzhou) Ltd (Filed With SEC on October 9, 2020)

Letter agreement amending M&A Advisory Agreement between the Company and A.G.P./Alliance Global Partners dated May 20, 2020 (Filed With SEC on August 14, 2020)

Exclusive License Agreement, by and between the Company and University of Louisville Research Foundation, Inc. dated as of June 9, 2020 (Filed With SEC on August 14, 2020)

Letter agreement (for payment date extension) between the Company and Sekisui Diagnostics, LLC dated June 23, 2020 (Filed With SEC on August 14, 2020)

Securities Purchase Agreement, dated August 2, 2020 (Filed With SEC on August 4, 2020)

Placement Agency Agreement between Qualigen Therapeutics, Inc. and A.G.P./Alliance Global Partners, dated August 2, 2020 (Filed With SEC on August 4, 2020)

Common Stock Purchase Warrant for 1,287,829 shares, dated August 4, 2020 (Filed With SEC on August 4, 2020)

Exclusive License Agreement, by and between Qualigen Therapeutics, Inc. and University of Louisville Research Foundation, Inc. dated as of July 17, 2020 (Filed With SEC on August 4, 2020)

Securities Purchase Agreement, dated July 8, 2020 - corrected (Filed With SEC on July 10, 2020)

Common Stock Purchase Warrant for 1,920,768 shares, dated July 10, 2020 (Filed With SEC on July 10, 2020)

Pre-Funded Common Stock Purchase Warrant for 1,920,768 shares, dated July 10, 2020 (Filed With SEC on July 10, 2020)

Securities Purchase Agreement between the Company and certain Purchasers, dated July 8, 2020 (Filed With SEC on July 9, 2020)

Form of Warrant expected to be issued July 10, 2020 (Filed With SEC on July 9, 2020)

Form of Pre-Funded Warrant expected to be issued July 10, 2020 (Filed With SEC on July 9, 2020)

Placement Agency Agreement between the Company and A.G.P./Alliance Global Partners, dated July 8, 2020 (Filed With SEC on July 9, 2020)

Standard template of Stock Option Agreement for use under 2020 Stock Incentive Plan (Filed With SEC on June 11, 2020)

Contingent Value Rights Agreement, dated May 22, 2020, by and among the Company, John Beck in the capacity of CVR Holders Representative and Andrew J. Ritter in his capacity as a... (Filed With SEC on May 29, 2020)

Executive Employment Agreement, by and between Qualigen, Inc. and Michael Poirier, dated as of February 1, 2017 and as amended on January 9, 2018 (Filed With SEC on May 29, 2020)

Executive Employment Agreement, by and between Qualigen, Inc. and Christopher Lotz, dated as of February 1, 2017 and as amended on January 9, 2018 (Filed With SEC on May 29, 2020)

Executive Employment Agreement, by and between Qualigen, Inc. and Shishir Sinha, dated as of February 1, 2017 and as amended on January 9, 2018 (Filed With SEC on May 29, 2020)

Consulting Agreement, by and between Qualigen, Inc. and GreenBlock Capital LLC, dated as of August 22, 2018 (Filed With SEC on May 29, 2020)

Amendment to Consulting Agreement, by and between Qualigen, Inc. and GreenBlock Capital LLC, dated as of March 6, 2020 (Filed With SEC on May 29, 2020)

Amendment No. 2 to Consulting Agreement, by and between Qualigen, Inc. and GreenBlock Capital LLC, dated as of May 3, 2020 (Filed With SEC on May 29, 2020)

Form of Warrant, issued by Qualigen, Inc. in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [pre-Merger] (Filed With SEC on May 29, 2020)

Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger] (Filed With SEC on May 29, 2020)

Securities Purchase Agreement, by and between Qualigen, Inc. and Alpha Capital Anstalt, dated May 20, 2020 (Filed With SEC on May 29, 2020)

Warrant, issued by Qualigen, Inc. in favor Alpha Capital Anstalt, dated May 22, 2020 [pre-Merger] (Filed With SEC on May 29, 2020)

Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020 [post-Merger] (Filed With SEC on May 29, 2020)

Notice of Grant of Stock Option / Stock Option Agreement, by and between the Company and Andrew J. Ritter, dated as of May 18, 2020 (Filed With SEC on May 29, 2020)

Notice of Grant of Stock Option / Stock Option Agreement, by and between the Company and Ira E. Ritter, dated as of May 18, 2020 (Filed With SEC on May 29, 2020)

Notice of Grant of Stock Option / Stock Option Agreement, by and between the Company and John Beck, dated as of May 18, 2020 (Filed With SEC on May 29, 2020)

Consulting Agreement, by and between the Company and Andrew J. Ritter, dated as of May 22, 2020 (Filed With SEC on May 29, 2020)

Consulting Agreement, by and between the Company and Stonehenge Partners, LLC, dated as of May 22, 2020 (Filed With SEC on May 29, 2020)

Consulting Agreement, by and between the Company and CFB Financial, Inc., dated as of May 22, 2020 (Filed With SEC on May 29, 2020)

2020 Stock Equity Incentive Plan (Filed With SEC on May 29, 2020)

Form of Indemnification Agreement - Qualigen, Inc (Filed With SEC on May 29, 2020)

Form of Lock-Up Agreement (Filed With SEC on May 29, 2020)

Description of Common Stock (Filed With SEC on March 31, 2020)

Form of Agreement to Exchange Warrants (Filed With SEC on February 21, 2020)

Form of CVR Agreement, by and among Ritter Pharmaceuticals, Inc., Andrew Ritter, in his capacity as the initial CVR Holders Representative, and Andrew Ritter, in his capacity as a... (Filed With SEC on January 21, 2020)

Agreement and Plan of Merger, dated January 15, 2020, by and among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen, Inc (Filed With SEC on January 21, 2020)

Form of Consent and Waiver with Series B Convertible Preferred Stockholders (Filed With SEC on November 14, 2019)

Sales Agreement dated November 6, 2019 between the Registrant and A.G.P./Alliance Global Partners (Filed With SEC on November 7, 2019)

Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter, dated October 15, 2019 (Filed With SEC on October 15, 2019)

Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and John W. Beck, dated October 15, 2019 (Filed With SEC on October 15, 2019)

Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter dated October 15, 2019 (Filed With SEC on October 15, 2019)

Amended and Restated Registration Rights Agreement, dated July 23, 2019, between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on July 24, 2019)

Amended and Restated Common Stock Purchase Agreement, dated July 23, 2019, between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on July 24, 2019)

Amended and Restated Registration Rights Agreement, dated July 23, 2019, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on July 24, 2019)

Amended and Restated Common Stock Purchase Agreement, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC, dated July 23, 2019 (Filed With SEC on July 24, 2019)

Form of Performance Restricted Stock Unit Award Agreement (Filed With SEC on April 1, 2019)

Amended and Restated Common Stock Purchase Agreement, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC, dated March 29, 2019 (Filed With SEC on April 1, 2019)

Securities Purchase Agreement, by and among Ritter Pharmaceuticals, Inc. and the Purchasers signatory thereto, dated October 30, 2018 (Filed With SEC on November 9, 2018)

Form of Common Stock Purchase Warrant (Filed With SEC on November 9, 2018)

Registration Rights Agreement, by and among Ritter Pharmaceuticals, Inc. and the Purchasers signatory thereto, dated October 30, 2018 (Filed With SEC on November 9, 2018)

Placement Agency Agreement, by and between Ritter Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners, dated October 30, 2018 (Filed With SEC on November 9, 2018)

Amended and Restated Offer Letter, dated June 26, 2018, by and between Ritter Pharmaceuticals, Inc and Andrew J. Ritter (Filed With SEC on August 14, 2018)

Agreement and General Release, dated June 26, 2018, by and between Ritter Pharmaceuticals, Inc. and Michael D. Step (Filed With SEC on July 2, 2018)

Consulting Agreement, dated June 26, 2018, by and between Ritter Pharmaceuticals, Inc. and Michael D. Step (Filed With SEC on July 2, 2018)

Offer Letter with John W. Beck, dated May 23, 2018 (Filed With SEC on May 29, 2018)

Executive Severance and Change in Control Agreement, by and between the Company and John W. Beck, effective May 24, 2018 (Filed With SEC on May 29, 2018)

Amended and Restated Master Services Agreement, dated May 1, 2018, by and between Ritter Pharmaceuticals, Inc. and Medpace , Inc (Filed With SEC on May 7, 2018)

First Amendment to Warrant Agency Agreement, dated May 1, 2018, by and between Ritter Pharmaceuticals, Inc. and Corporate Stock Transfer (Filed With SEC on May 7, 2018)

Specimen stock certificate of Ritter Pharmaceuticals, Inc (Filed With SEC on March 22, 2018)

Underwriting Agreement, dated September 29, 2017, between Ritter Pharmaceuticals, Inc. and Aegis Capital Corp., as representative of the several underwriters named therein (Filed With SEC on October 4, 2017)

Warrant Agency Agreement, dated September 29, 2017 by and between Ritter Pharmaceuticals, Inc. and Corporate Stock Transfer, Inc. (including the form of warrant certificate) (Filed With SEC on October 4, 2017)

RITTERPHARMACEUTICALS, INC. WARRANTAGENCY AGREEMENT (Filed With SEC on September 28, 2017)

Amendment to 2015 Equity Incentive Plan (Filed With SEC on September 15, 2017)

UNDERWRITINGAGREEMENT between RITTERPHARMACEUTICALS, INC. and AEGISCAPITAL CORP., asRepresentative of the Several Underwriters (Filed With SEC on July 18, 2017)

RITTERPHARMACEUTICALS, INC. WARRANTAGENCY AGREEMENT (Filed With SEC on July 18, 2017)

SECOND AMENDMENT TO 2015 EQUITY INCENTIVEPLAN (Effective June 2, 2017) (Filed With SEC on June 6, 2017)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on May 9, 2017)

COMMONSTOCK PURCHASE AGREEMENT (Filed With SEC on May 9, 2017)

UNDERWRITINGAGREEMENT between RITTERPHARMACEUTICALS, INC. and AEGISCAPITAL CORP., asRepresentative of the Several Underwriters (Filed With SEC on October 27, 2016)

AMENDMENTTO 2015 EQUITY INCENTIVE PLAN (EffectiveJune 3, 2016) (Filed With SEC on June 6, 2016)

RITTERPHARMACEUTICALS, INC. AMENDMENTNo. 4 TO AMENDED AND RESTATED INVESTORS’ RIGHTSAGREEMENT (Filed With SEC on December 31, 2015)

RITTERPHARMACEUTICALS, INC. COMMONSTOCK PURCHASE WARRANT (Filed With SEC on December 31, 2015)

MASTERSERVICE AGREEMENT (Filed With SEC on December 31, 2015)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on December 21, 2015)

COMMONSTOCK PURCHASE AGREEMENT (Filed With SEC on December 21, 2015)

LEASE (Filed With SEC on November 10, 2015)

AMENDMENT No. 2 TO CLINICAL SUPPLY AND COOPERATION AGREEMENT (Filed With SEC on November 10, 2015)

LETTER OFAGREEMENT Date: October 20, 2015 (Filed With SEC on November 10, 2015)

EXECUTIVE SEVERANCE & CHANGE IN CONTROL AGREEMENT (Filed With SEC on August 12, 2015)

RITTERPHARMACEUTICALS, INC. AMENDMENTNo. 4 TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (Filed With SEC on May 22, 2015)

EXECUTIVE SEVERANCE & CHANGE IN CONTROL AGREEMENT (Filed With SEC on May 22, 2015)

UNDERWRITING AGREEMENT between RITTER PHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on May 8, 2015)

Form of Representative’s Warrant Agreement (Filed With SEC on May 8, 2015)

RITTER PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN ARTICLE1. PURPOSE (Filed With SEC on May 8, 2015)

RITTER PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on April 24, 2015)

Clinical Supply and Cooperation Agreement BetweenRitter & RSM/Inalco CLINICAL SUPPLY AND COOPERATION AGREEMENT (also referred to as “CSCA”) BETWEEN (Filed With SEC on April 24, 2015)

AMENDMENT 1 To the Clinical Supply and Cooperation Agreement(hereinafter “CSCA”) entered into between: (Filed With SEC on April 24, 2015)

RITTER PHARMACEUTICALS,INC. AMENDED AND RESTATED INVESTORS’RIGHTS AGREEMENT (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (Filed With SEC on March 23, 2015)

RITTERPHARMACEUTICALS, INC. AMENDMENTNo. 3 TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (Filed With SEC on March 23, 2015)

OFFICELEASE Between DOUGLAS EMMETT 1997, LLC, a Delaware limited liability company as Landlord and RITTER PHARMACEUTICALS, INC., a Delaware corporation as Tenant Date June 25, 2013 (Filed With SEC on March 23, 2015)

Exhibit A (Filed With SEC on March 23, 2015)

Ritter Pharmaceuticals, Inc. Executive Compensation Plan (Filed With SEC on March 23, 2015)

EXECUTIVE SEVERANCE & CHANGE IN CONTROL AGREEMENT (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS, INC. 2008 STOCK PLAN (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS, INC. 2009 STOCK PLAN (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS, INC. 2008 STOCK PLAN STOCK OPTION AGREEMENT (Filed With SEC on March 23, 2015)

RESEARCH AND DEVELOPMENT AGREEMENT &LICENSE (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS,INC. AMENDMENT NO. 1 TO RESEARCH AND DEVELOPMENTAGREEMENT & LICENSE (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS,INC. AMENDMENT NO. 2 TO RESEARCH AND DEVELOPMENTAGREEMENT & LICENSE (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS,INC. AMENDMENT NO. 3 TO RESEARCH AND DEVELOPMENTAGREEMENT & LICENSE (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS,INC. AMENDMENT NO. 4 TO RESEARCH AND DEVELOPMENTAGREEMENT & LICENSE (Filed With SEC on March 23, 2015)

PUT AND CALL OPTION AGREEMENT (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS,INC. SUBORDINATED CONVERTIBLEPROMISSORY NOTE (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS, INC. SUBORDINATED CONVERTIBLE PROMISSORY NOTE (Filed With SEC on March 23, 2015)

UNSECURED PROMISSORY NOTE (Filed With SEC on March 23, 2015)

RITTER PHARMACEUTICALS, INC. SUBORDINATED CONVERTIBLE PROMISSORY NOTE (Filed With SEC on March 23, 2015)

RitterPharmaceuticals, Inc. SeriesC Preferred Stock and Warrant Purchase Agreement (Filed With SEC on March 23, 2015)

Category

Industry

Companies

Contracts

RITTER PHARMACEUTICALS INC Contracts & Agreements